PT - JOURNAL ARTICLE AU - Alexandra L Whittaker AU - Rebecca P George AU - Lucy O’Malley TI - Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: A systematic review and meta-analysis AID - 10.1101/2021.08.17.21262190 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.17.21262190 4099 - http://medrxiv.org/content/early/2021/08/20/2021.08.17.21262190.short 4100 - http://medrxiv.org/content/early/2021/08/20/2021.08.17.21262190.full AB - Breast cancer survival rates have markedly improved. Consequently, survivorship issues have received increased attention. One common sequela of treatment is chemotherapy- induced cognitive impairment (CICI). CICI causes a range of impairments that can have a significant negative impact on quality of life. Knowledge of the prevalence of this condition is required to inform survivorship plans, and ensure adequate resource allocation and support is available for sufferers.Objective To estimate the prevalence of cognitive impairment following chemotherapy treatment for breast cancer.Methods Medline, Scopus, CINAHL and PSYCHInfo were searched for eligible studies which included prevalence data on CICI, as ascertained though the use of self-report, or neuropsychological tests. Methodological quality of included studies was assessed. Findings were synthesised narratively, with meta-analyses being used to calculate pooled prevalence when impairment was assessed by neuropsychological tests.Results and discussion The review included 52 studies. Time-points considered ranged from the chemotherapy treatment period to greater than 10 years after treatment cessation. Summary prevalence figures (across time-points) using self-report, short cognitive screening tools and neuropsychological test batteries were 44%, 16% and 21-34% respectively (very low GRADE evidence).Conclusion Synthesised findings demonstrate that 1 in 3 breast cancer survivors may have clinically significant cognitive impairment. Prevalence is higher when self-report based on patient experience is considered. This review highlights a number of study design issues that may have contributed to the low certainty rating of the evidence. Future studies should take a more consistent approach to the criteria used to assess impairment. Larger studies are urgently needed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialMeta-analysis of published studiesFunding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. ALW was supported by a NHMRC Peter Doherty Biomedical Research Fellowship (APP1140072). RPG was supported by an Australian Government Research Training Program ScholarshipAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval not needed since meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are included in manuscript and supporting files